1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Medicines Patent Pool Centers On Consolidation In Its New Three-Year Strategy

Organization Aims To Conclude 10 Licenses, Develop Five Products And Transfer mRNA Tech To 10 Manufacturers

 
• By Chloe Kent

The Medicines Patent Pool’s new strategy could open the door to significant new opportunities for generic drug suppliers across low- and middle-income countries, as it explores its remit in new fields such as biologics, early-stage drug development and even – possibly – antimicrobial resistance.

2023, 2024 and 2025 sprayed onto a road
MPP has opted for a consolidated, three-year strategy • Source: Shutterstock

“This is my last job,” said Medicines Patent Pool executive director Charles Gore. “I’ve worked in global public health for the last 20 plus years and I am only interested in what difference we can make as an organization. I’m not interested in empire building or the whole kind of ego trip that there’s unfortunately a bit too much of in public health. It’s about just seeing where we can make a difference.”

The MPP has recently announced its new strategy, which will span from this year through to 2025, opting for a shorter plan of action than it might have done otherwise – the organization would typically work

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.